Ann: US patent allowed for CHM 0201 (CORE-NK) technology, page-8

Another step towards a future commercialization, important, but hardly any motivation to buy for new investors.

Anyway, NK is used to treat some type of blood cancers where CD19 CAR-Ts won't work. Filling that gap is worth a lot and definitely more than what CHM is currently valued at. The AML trials could be the jump board although the tech has already proven to produce remarkable results. MD Anderson has a very high reputation, choosing CHM's 0201 isn't a result of a "Texas Saloon" lunch, it has been chosen for a reason.

GLTA